CA2995094A1 - Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury - Google Patents

Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury Download PDF

Info

Publication number
CA2995094A1
CA2995094A1 CA2995094A CA2995094A CA2995094A1 CA 2995094 A1 CA2995094 A1 CA 2995094A1 CA 2995094 A CA2995094 A CA 2995094A CA 2995094 A CA2995094 A CA 2995094A CA 2995094 A1 CA2995094 A1 CA 2995094A1
Authority
CA
Canada
Prior art keywords
calcium
substituted
c6alkyl
heteroaryl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2995094A
Other languages
English (en)
French (fr)
Inventor
Kenneth Stauderman
Michael Dunn
Sudarshan Hebbar
Midori YENARI
Rachid KACIMI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Calcimedica Inc
US Department of Veterans Affairs
Original Assignee
Calcimedica Inc
US Department of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calcimedica Inc, US Department of Veterans Affairs filed Critical Calcimedica Inc
Publication of CA2995094A1 publication Critical patent/CA2995094A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2995094A 2015-08-07 2016-08-05 Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury Pending CA2995094A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562202751P 2015-08-07 2015-08-07
US62/202,751 2015-08-07
PCT/US2016/045846 WO2017027400A1 (en) 2015-08-07 2016-08-05 Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury

Publications (1)

Publication Number Publication Date
CA2995094A1 true CA2995094A1 (en) 2017-02-16

Family

ID=57984283

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2995094A Pending CA2995094A1 (en) 2015-08-07 2016-08-05 Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury

Country Status (7)

Country Link
US (2) US10478435B2 (enExample)
EP (1) EP3331525B1 (enExample)
JP (1) JP6738575B2 (enExample)
AU (1) AU2016306301B2 (enExample)
CA (1) CA2995094A1 (enExample)
DK (1) DK3331525T3 (enExample)
WO (1) WO2017027400A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10703722B2 (en) 2010-04-27 2020-07-07 Calcimedica, Inc. Compounds that modulate intracellular calcium
CN114712513B (zh) 2015-02-27 2026-02-10 钙医学公司 胰腺炎治疗
AU2016306301B2 (en) 2015-08-07 2021-02-11 Calcimedica, Inc. Use of CRAC channel inhibitors for the treatment of stroke and traumatic brain injury
AR109595A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
IL292977A (en) 2016-09-09 2022-07-01 Incyte Corp Pyrazolopyridine derivatives as modulators of hpk1 and their use in cancer therapy
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
JP7526673B2 (ja) 2018-02-20 2024-08-01 インサイト・コーポレイション がんを治療するためのｈｐｋ１阻害剤としてのｎ－（フェニル）－２－（フェニル）ピリミジン－４－カルボキサミド誘導体及び関連化合物
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
ES2973117T3 (es) 2018-09-25 2024-06-18 Incyte Corp Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR
CN111138426B (zh) * 2018-11-02 2023-03-10 安徽中科拓苒药物科学研究有限公司 吲唑类激酶抑制剂及其用途
CN114450274A (zh) 2019-07-11 2022-05-06 伊斯凯普生物公司 作为lrrk2抑制剂的吲唑及氮杂吲唑
KR20220059480A (ko) 2019-08-06 2022-05-10 인사이트 코포레이션 고체 형태의 hpk1 억제제
EP4043450A4 (en) * 2019-09-25 2023-10-25 Medshine Discovery Inc. 2h-benzopyran derivatives as crac inhibitors
US12544371B2 (en) 2020-03-20 2026-02-10 Calcimedica, Inc. Methods and compositions for treating acute lung injury and acute respiratory distress syndrome
EP3912972A1 (en) * 2020-05-19 2021-11-24 Centre Hospitalier Régional et Universitaire de Brest Soce inhibitors and therapeutic uses thereof
US12522589B2 (en) 2020-11-13 2026-01-13 Calcimedica, Inc. Synthesis of CRAC channel inhibitors

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2194213T3 (es) 1996-08-09 2003-11-16 Boehringer Ingelheim Pharma Beta-carbolinas-4- sustituidas en calidad de inmunomoduladores.
AU751139B2 (en) 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
EP1068187A1 (en) 1998-04-08 2001-01-17 Abbott Laboratories Pyrazole inhibitors of cytokine production
CA2332957A1 (en) 1998-06-05 1999-12-09 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
US20010044445A1 (en) 1999-04-08 2001-11-22 Bamaung Nwe Y. Azole inhibitors of cytokine production
BR0013469B1 (pt) 1999-08-20 2011-01-25 amidas aromáticas heterocìclicas fungicidas, composição fungicida compreendendo as mesmas, bem como método para o controle ou a prevenção de infestação fúngica.
JP3910319B2 (ja) 1999-09-13 2007-04-25 株式会社小糸製作所 自動車用灯具
EP1143013A1 (en) 2000-04-03 2001-10-10 Warner-Lambert Company Methods and compositions for screening Icrac modulators
GB0225554D0 (en) 2002-11-01 2002-12-11 Syngenta Participations Ag Chemical compounds
JP4896518B2 (ja) 2002-12-13 2012-03-14 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド ニコチンアミド系キナーゼ阻害薬
WO2004056774A2 (en) 2002-12-19 2004-07-08 Neurogen Corporation Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators
US7645588B2 (en) * 2003-03-04 2010-01-12 Calcimedica, Inc. Composition comprising a cell comprising a STIM1 protein and an agent that modulates intracellular calcium and methods of use
EP1653968A4 (en) 2003-07-23 2006-09-06 Synta Pharmaceuticals Corp METHOD FOR MODULATING CALCIUMION RELIEF ACTIVATED CALCIUMION CHANNELS
DE102004005785A1 (de) 2004-02-06 2005-08-25 Bayer Cropscience Ag 2-Halogenfuryl/thienyl-3-carboxamide
CN101083985A (zh) 2004-09-21 2007-12-05 幸讬制药公司 用于炎症及免疫相关用途的化合物
MX2007008290A (es) 2005-01-07 2008-02-15 Synta Pharmaceuticals Corp Compuestos para inflamacion y usos inmuno-relacionados.
US8518950B2 (en) 2005-01-25 2013-08-27 Synta Pharmaceuticals Corp. 2-amido pyrazines for inflammation and immune related uses
WO2006081389A1 (en) 2005-01-25 2006-08-03 Synta Pharmaceuticals Corp. Thiophene compounds for inflammation and immune-related uses
SG164378A1 (en) 2005-02-17 2010-09-29 Synta Pharmaceuticals Corp Compounds for the treatment of proliferative disorders
EP2527337A1 (en) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US20070105867A1 (en) 2005-09-21 2007-05-10 Bristol-Myers Squibb Company Oral administration of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof
NL2000284C2 (nl) * 2005-11-04 2007-09-28 Pfizer Ltd Pyrazine-derivaten.
EP2774925B1 (en) 2005-11-08 2016-12-28 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of ATP-binding cassette transporters
EP1984400B1 (en) 2006-01-05 2012-11-28 Immune Disease Institute, Inc. Regulators of nfat
TWI444370B (zh) 2006-01-25 2014-07-11 Synta Pharmaceuticals Corp 用於發炎及免疫相關用途之噻唑及噻二唑化合物
CA2640091A1 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Vinyl-phenyl derivatives for inflammation and immune-related uses
WO2007087442A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted biaryl compounds for inflammation and immune-related uses
CA2640090A1 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted aromatic compounds for inflammation and immune-related uses
CA2639913A1 (en) 2006-01-25 2007-08-02 Synta Pharmaceutical Corp. Phenyl and pyridyl compounds for inflammation and immune-related uses
DK1984338T3 (da) 2006-01-31 2013-04-22 Synta Pharmaceuticals Corp Pyridylphenylforbindelser til inflammations- og immunrelaterede anvendelser
US7951824B2 (en) 2006-02-17 2011-05-31 Hoffman-La Roche Inc. 4-aryl-pyridine-2-carboxyamide derivatives
AU2007227210A1 (en) 2006-03-20 2007-09-27 Synta Pharmaceuticals Corp. Benzoimidazolyl-parazine compounds for inflammation and immune-related uses
CA2646886A1 (en) 2006-03-23 2007-10-04 Synta Pharmaceuticals Corp. Benzimidazolyl-pyridine compounds for inflammation and immune-related uses
EP2004627A2 (en) 2006-04-10 2008-12-24 Arena Pharmaceuticals, Inc. 3-pyridinyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
NZ601730A (en) * 2006-06-26 2014-04-30 Akebia Therapeutics Inc Prolyl hydroxylase inhibitors and methods of use
AU2007322116B2 (en) 2006-11-13 2013-01-10 Synta Pharmaceuticals Corp. Cyclohexenyl-aryl compounds for inflammation and immune-related uses
TW200901961A (en) 2007-02-16 2009-01-16 Synta Pharmaceuticals Corp Substituted fused-ring compounds for inflammation and immune-related uses
WO2008148108A1 (en) 2007-05-24 2008-12-04 Calcimedica, Inc. Calcium channel proteins and uses thereof
TWI444186B (zh) 2007-08-01 2014-07-11 Synta Pharmaceuticals Corp 用於發炎與免疫相關用途之雜環－芳基化合物
WO2009017831A1 (en) 2007-08-01 2009-02-05 Synta Pharmaceuticals Corp. Vinyl-aryl derivatives for inflammation and immune-related uses
CA2695621A1 (en) 2007-08-09 2009-02-12 Merck Sharp & Dohme Corp. Pyridine carboxamide orexin receptor antagonists
JP5411141B2 (ja) 2007-09-10 2014-02-12 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
EP2240029A4 (en) 2008-01-07 2012-08-22 Synta Pharmaceuticals Corp COMPOUNDS FOR USE AGAINST INFLAMMATORY AND IMMUNOMIC DISEASES
FR2927330B1 (fr) * 2008-02-07 2010-02-19 Sanofi Aventis Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii
EP2265574A1 (en) 2008-02-29 2010-12-29 Array Biopharma, Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
EP2262532A1 (en) * 2008-03-20 2010-12-22 CSL Behring GmbH The calcium sensor STIM1 and the platelet SOC channel Orai1 (CRACM1) are essential for pathological thrombus formation
US20100016598A1 (en) 2008-07-16 2010-01-21 Wyeth Alpha7 nicotinic acetylcholine receptor inhibitors
CA2734500A1 (en) 2008-08-27 2010-03-11 Calcimedica Inc. Compounds that modulate intracellular calcium
WO2010034011A2 (en) 2008-09-22 2010-03-25 Calcimedica, Inc. Phenylthiophenyldihydrobenzothiazepine inhibitors of store operated calcium release
US8524763B2 (en) 2008-09-22 2013-09-03 Calcimedica, Inc. Inhibitors of store operated calcium release
AU2009300317A1 (en) 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
CA2739303A1 (en) 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
WO2010048559A2 (en) * 2008-10-24 2010-04-29 Calcimedica Inc. Phenylpyrazole inhibitors of store operated calcium release
JP2012524755A (ja) 2009-04-24 2012-10-18 グラクソ グループ リミテッド Ｃｒａｃチャネル阻害剤としてのｎ−ピラゾリルカルボキサミド
EP2421834A1 (en) 2009-04-24 2012-02-29 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
US8618307B2 (en) 2009-09-16 2013-12-31 Calcimedica, Inc. Compounds that modulate intracellular calcium
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
AU2010321832B2 (en) 2009-11-20 2014-08-14 Amgen Inc. Anti-Orai1 antigen binding proteins and uses thereof
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
HUE029570T2 (en) 2010-04-27 2017-03-28 Calcimedica Inc Intracellular calcium modifying compounds
EP2563759B1 (en) 2010-04-27 2022-04-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
US10703722B2 (en) 2010-04-27 2020-07-07 Calcimedica, Inc. Compounds that modulate intracellular calcium
CN103180316A (zh) 2010-08-27 2013-06-26 钙医学公司 调节细胞内钙的化合物
EP2704701B1 (en) * 2011-05-03 2018-01-03 PRCL Research Inc. Compounds for inflammation and immune-related uses
US20130143927A1 (en) 2011-06-10 2013-06-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
US20120316182A1 (en) * 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9856240B2 (en) * 2011-10-19 2018-01-02 Calcimedica, Inc. Compounds that modulate intracellular calcium
AU2012325901A1 (en) * 2011-10-19 2014-05-15 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9399638B2 (en) 2012-05-02 2016-07-26 Lupin Limited Substituted pyridine compounds as CRAC modulators
WO2014043715A1 (en) 2012-09-17 2014-03-20 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
CN114712513B (zh) 2015-02-27 2026-02-10 钙医学公司 胰腺炎治疗
AU2016306301B2 (en) 2015-08-07 2021-02-11 Calcimedica, Inc. Use of CRAC channel inhibitors for the treatment of stroke and traumatic brain injury
CA3051420A1 (en) 2017-01-26 2018-08-02 Calcimedica, Inc. Crac channel inhibitor compositions

Also Published As

Publication number Publication date
EP3331525A1 (en) 2018-06-13
WO2017027400A1 (en) 2017-02-16
EP3331525A4 (en) 2019-04-03
AU2016306301A1 (en) 2018-03-08
US10478435B2 (en) 2019-11-19
DK3331525T3 (da) 2020-12-14
JP6738575B2 (ja) 2020-08-12
US20200101069A1 (en) 2020-04-02
JP2018529650A (ja) 2018-10-11
US20180235959A1 (en) 2018-08-23
AU2016306301B2 (en) 2021-02-11
EP3331525B1 (en) 2020-10-07

Similar Documents

Publication Publication Date Title
AU2016306301B2 (en) Use of CRAC channel inhibitors for the treatment of stroke and traumatic brain injury
CA2797663C (en) Compounds that modulate intracellular calcium
US10106529B2 (en) Compounds that modulate intracellular calcium
US8372991B2 (en) Trisubstituted thiophenes that modulate intracellular calcium
US11905248B2 (en) Compounds that modulate intracellular calcium
US9512116B2 (en) Compounds that modulate intracellular calcium
MX2013002304A (es) Compuestos que modulan el calcio intracelular.
WO2013059677A1 (en) Compounds that modulate intracellular calcium
AU2012325901A1 (en) Compounds that modulate intracellular calcium
AU2016201832A1 (en) Compounds that modulate intracellular calcium
EP2477982A2 (en) Compounds that modulate intracellular calcium
WO2011109551A2 (en) Compounds that modulate intracellular calcium
WO2014043715A1 (en) Compounds that modulate intracellular calcium

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210804

C12 Request for application revival rejected

Free format text: ST27 STATUS EVENT CODE: N-6-6-C10-C12-C109 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST REFUSED (DUE CARE)

Effective date: 20240704

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20240828

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20240912

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250731

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250731

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260206

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: T-6-6-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20260306